Relationship of the epithelial-mesenchimal transition expression markers with clinical and morphological parameters of colon cancer

The treatment of colon cancer with a mesenchymal-like phenotype poses a great challenge. Purpose of the study: to research expression of FRMD6, ZEB1, HTR2B, CDX2 in the primary tumor tissue with relation of the clinical and pathological features of colon cancer. Material and methods. a combined analysis of the expression of FRMD6, ZEB1, HTR2B, CDX2 with pathological criteria was performed in 100 patients with T1–4bN0–2bM0  colon  cancer.  Results  of  the  study  show  that  tumors  with  mesenchymal  signs  are characterized by a large size of the primary tumor, a high grade of differentiation, regional metastases, and eventually advanced stage of the disease. The frequency and expression levels of FRMD6, ZEB1 and HTR2B are depended of grade of adenocarcinoma. in cases with positive expression and a high percentage of expression of these proteins in the cancer cells, the degree of tumor morphological anaplasia increases. Conclusion. The study made it possible to reveal the relationship of IHC markers (FRMD6, ZEB1, HTR2B, CDX2) with tumor characteristics that determine the outcome. The studied markers may have prognostic and predictive value in treatment approaches of colon cancer.

1. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. doi: 10.1002/ijc.33588.

2. The state of cancer care to the population of Russia in 2019. Moscow, 2020. P. 72–5. (in Russian).

3. Odintsova I.N., Cheremisina O.V., Pisareva L.F., Spivakova I.O., Vusik M.V. Epidemiology of colorectal cancer in Tomsk region. Siberian Journal of Oncology. 2017; 16(4): 89–95. (in Russian). doi: 10.21294/1814-4861-2017-16-4-89-95.

4. Hao Y., Baker D., Ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11): 2767. doi: 10.3390/ijms20112767.

5. Karlsson M.C., Gonzalez S.F., Welin J., Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol. 2017; 11(7): 781–91. doi: 10.1002/1878-0261.12092.

6. Erin N., Grahovac J., Brozovic A., Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020; 53. doi: 10.1016/j.drup.2020.100715.

7. Xu W., Yang Z., Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015; 9(4): 317–24. doi: 10.1080/19336918.2015.1016686.

8. Wilson M.M., Weinberg R.A, Lees J.A., Guen V.J. Emerging Mechanisms by which EMT Programs Control Stemness. Trends Cancer. 2020; 6(9): 775–80. doi: 10.1016/j.trecan.2020.03.011.

9. Hapke R.Y., Haake S.M. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett. 2020; 487: 10–20. doi: 10.1016/j.canlet.2020.05.012.

10. Goossens S., Vandamme N., Van Vlierberghe P., Berx G. EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017; 1868(2): 584–91. doi: 10.1016/j.bbcan.2017.06.006.

11. Williams E.D., Gao D., Redfern A., Thompson E.W. Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat Rev Cancer. 2019; 19(12): 716–32. doi: 10.1038/s41568-019-0213-x.

12. Feng Y.L., Chen D.Q., Vaziri N.D., Guo Y., Zhao Y.Y. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev. 2020; 40(1): 54–78. doi: 10.1002/med.21596.

13. Kumari N., Reabroi S., North B.J. Unraveling the Molecular Nexus between GPCRs, ERS, and EMT. Mediators Inflamm. 2021; 2021. doi: 10.1155/2021/6655417.

14. Lu Y., Ding Y., Wei J., He S., Liu X., Pan H., Yuan B., Liu Q., Zhang J. Anticancer effects of Traditional Chinese Medicine on epithelial-mesenchymal transition EMT in breast cancer: Cellular and molecular targets. Eur J Pharmacol. 2021; 907. doi: 10.1016/j.ejphar.2021.174275.

15. Dongre A., Weinberg R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019; 20(2): 69–84. doi: 10.1038/s41580-018-0080-4.

16. Valenzuela G., Canepa J., Simonetti C., Solo de Zaldívar L., Marcelain K., González-Montero J. Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach. World J Clin Oncol. 2021; 12(11): 1000–8. doi: 10.5306/wjco.v12.i11.1000.

17. Roseweir A.K., Kong C.Y., Park J.H., Bennett L., Powell A.G.M.T., Quinn J., van Wyk H.C., Horgan P.G., McMillan D.C., Edwards J., Roxburgh C.S. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer. 2019; 144(1): 150–9. doi: 10.1002/ijc.31739.

18. Sinyansky L.E., Vtorushin S.V., Patalyak S.V., Afanasyev S.G. Prognostic role of molecular sybtypes of colon cancer. A current view on the problem. Siberian Journal of Oncology. 2021; 20(3): 107–14. (in Russian). doi: 10.21294/1814-4861-2021-20-3-107-114.

19. Wang F., Sun G., Peng C., Chen J., Quan J., Wu C., Lian X., Tang W., Xiang D. ZEB1 promotes colorectal cancer cell invasion and disease progression by enhanced LOXL2 transcription. Int J Clin Exp Pathol. 2021; 14(1): 9–23.

20. Soll C., Riener M.O., Oberkofler C.E., Hellerbrand C., Wild P.J., DeOliveira M.L., Clavien P.A. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 2012; 18(21): 5902–10. doi: 10.1158/1078-0432.CCR-11-1813.

21. Ebrahimkhani M.R., Oakley F., Murphy L.B., Mann J., Moles A., Perugorria M.J., Ellis E., Lakey A.F., Burt A.D., Douglass A., Wright M.C., White S.A., Jaffré F., Maroteaux L., Mann D.A. Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease. Nat Med. 2011; 17(12): 1668–73. doi: 10.1038/nm.2490.

22. Ye D., Xu H., Tang Q., Xia H., Zhang C., Bi F. The role of 5-HT metabolism in cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876(2). doi: 10.1016/j.bbcan.2021.188618.

23. Yu J., Li S., Xu Z., Guo J., Li X., Wu Y., Zheng J., Sun X. CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression. Br J Cancer. 2021; 124(1): 270–80. doi: 10.1038/s41416-020-01148-1.

24. Gunn-Moore F.J., Welsh G.I., Herron L.R., Brannigan F., Venkateswarlu K., Gillespie S., Brandwein-Gensler M., Madan R., Tavaré J.M., Brophy P.J., Prystowsky M.B., Guild S. A novel 4.1 ezrin radixin moesin (FERM)-containing protein, ‘Willin’. FEBS Lett. 2005; 579(22): 5089–94. doi: 10.1016/j.febslet.2005.07.097.

25. De Sousa E. Melo F., Wang X., Jansen M., Fessler E., Trinh A., de Rooij L.P., de Jong J.H., de Boer O.J., van Leersum R., Bijlsma M.F., Rodermond H., van der Heijden M., van Noesel C.J., Tuynman J.B., Dekker E., Markowetz F., Medema J.P., Vermeulen L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013; 19(5): 614–8. doi: 10.1038/nm.3174.